PTC's $500 Million Refinancing Buys Time Until 2031-But Investors Still Need the 2026 Bill Paid

Refinancing moves the maturity from 2026 to 2031, but the real test is execution

PTC Therapeutics is replacing a 2026 maturity with new 2031 convertible notes. That extends the timeline, but it does not settle the investor question: can the company use that extra time to build enough operating performance to make the eventual conversion economics easier to absorb?